From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Abcam: clever science + an upcoming Nasdaq listing = ?...

By Chris Bailey | Monday 14 September 2020


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I have always been quite impressed by Abcam (ABC), which I described back in April as ‘a thematic growth investment – and not for widows, orphans or neophyte investors – with an earnings multiple of around 30 times and a play on where profitability might be in a few years time off clever science discoveries and processes’. In that article I observed that following the lead of a big institutional investor who negotiated buying a slug of the company at 1100p. Since then the stock has returned to the 1300p+ range and quite rightly so…

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 17:57:24